424B7
Filed pursuant to Rule 424(b)(7)
SEC File No. 333-139827
PROSPECTUS SUPPLEMENT NO. 8
(To Prospectus dated January 5, 2007)
571,608 Shares
BioMed Realty Trust, Inc.
Common Stock
Issuable upon Exchange of BioMed Realty, L.P. 4.50% Exchangeable Senior Notes due 2026
 
This prospectus supplement no. 8 supplements and amends the prospectus dated January 5, 2007, relating to the resale from time to time by certain selling stockholders of shares of our common stock that may be issued upon the exchange or redemption of BioMed Realty, L.P.’s 4.50% Exchangeable Senior Notes due 2026.
You should read this prospectus supplement no. 8 in conjunction with the prospectus. This prospectus supplement no. 8 is not complete without, and may not be delivered or used except in conjunction with, the prospectus, including any amendments or supplements to it. This prospectus supplement no. 8 is qualified by reference to the prospectus, except to the extent that the information provided by this prospectus supplement no. 8 supersedes information contained in the prospectus.
Selling stockholders, including their transferees, pledgees or donees or their successors, may from time to time offer and sell pursuant to the prospectus and any accompanying prospectus supplement any or all of the shares of our common stock which we may issue upon the exchange or redemption of the notes.
The following table sets forth information, as of March 13, 2009, with respect to the selling stockholders and the number of shares of our common stock that would become beneficially owned by each stockholder should we issue our common stock to such selling stockholder that may be offered pursuant to this prospectus upon the exchange or redemption of the notes. The information is based on information provided by or on behalf of the selling stockholders. The selling stockholders may offer all, some or none of the shares of our common stock which we may issue upon the exchange or redemption of the notes. Because the selling stockholders may offer all or some portion of such shares of our common stock, we cannot estimate the number of shares of our common stock that will be held by the selling stockholders upon termination of any of these sales. In addition, the selling stockholders identified below may have sold, transferred or otherwise disposed of all or a portion of their notes or shares of our common stock since the date on which they provided the information regarding their notes in transactions exempt from the registration requirements of the Securities Act of 1933, as amended.
The number of shares of our common stock issuable upon the exchange or redemption of the notes shown in the table below assumes exchange of the full amount of notes held by each selling stockholder at the maximum exchange rate of 31.7561 shares of our common stock per $1,000 principal amount of notes and a cash payment in lieu of any fractional share. This exchange rate is subject to adjustment in certain events. Accordingly, the number of shares of our common stock issued upon the exchange or redemption of the notes may increase or decrease from time to time. The number of shares of our common stock owned by the other selling stockholders or any future transferee from any such holder assumes that they do not beneficially own any shares of common stock other than the common stock that we may issue to them upon the exchange or redemption of the notes.
Based upon information provided by the selling stockholders, none of the selling stockholders identified below nor any of their affiliates, officers, directors or principal equity holders has held any positions or office or has had any material relationship with us within the past three years.
To the extent any of the selling stockholders identified below are broker-dealers, they may be deemed to be, under interpretations of the staff of the Securities and Exchange Commission, “underwriters” within the meaning of the Securities Act of 1933, as amended.

 

 

 

                             
    Number of                      
    Shares     Percentage of           Number of   Percentage of
    Beneficially     Shares           Shares   Shares
    Owned     Beneficially   Number of     Beneficially   Beneficially
    Prior to the     Owned Prior to   Shares Offered     Owned After   Owned After the
Name   Offering     the Offering(1)   Hereby     the Offering(2)   Offering(1)(2)
DBX—Convertible Arbitrage 13 Fund(3)
     8,986     *     8,986     —   *
D. E. Shaw Oculus Portfolios, L.L.C.(4)
     190,536     *     190,536     —   *
Waterstone Market Neutral Mac 51 Fund, Ltd(3)
     90,473     *     90,473     —   *
Waterstone Market Neutral Master Fund, Ltd(3)
     281,613     *     281,613     —   *
Total
     571,608     *     571,608     —   *
*   Less than 1%.
 
(1)   Based on a total of 81,180,596 shares of our common stock outstanding as of March 13, 2009.
 
(2)   Assumes the selling stockholder sells all of its shares of our common stock offered pursuant to this prospectus.
 
(3)   Waterstone Capital Management, L.P. serves as the investment adviser for each of DBX—Convertible Arbitrage 13 Fund, Waterstone Market Neutral Mac 51 Fund, Ltd and Waterstone Market Neutral Master Fund, Ltd. Shawn Bergerson has voting and investment control over the securities held by each of DBX—Convertible Arbitrage 13 Fund, Waterstone Market Neutral Mac 51 Fund, Ltd and Waterstone Market Neutral Master Fund, Ltd.
 
(4)   D. E. Shaw & Co. L.P., as investment adviser, has voting and investment control over the securities owned by D. E. Shaw Oculus Portfolios, L.L.C. Anne Dinning, Julius Gaudio, Lou Salkind, Maximilian Stone and Eric Wepsic, or their designees, exercise voting and investment control over the securities held by D. E. Shaw Oculus Portfolios, L.L.C., on D. E. Shaw & Co. L.P.’s behalf. D. E. Shaw Oculus Portfolios, L.L.C. is an affiliate of a registered broker-dealer.
You should consider the risks that we have described in “Risk Factors” beginning on page 2 of the prospectus and included in our periodic reports and other information that we file with the Securities and Exchange Commission before investing in our securities.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of the prospectus or this prospectus supplement no. 8. Any representation to the contrary is a criminal offense.
The date of this prospectus supplement no. 8 is March 13, 2009.

 

2